Regeneron and Sanofi expanded their antibody collaboration with four new long-acting immunology antibodies. Regeneron receives $1 billion upfront and up to $7 billion in milestones. The companies will split development costs and profits 50:50 globally.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
